Sélim Corm

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini et al. · New England Journal of Medicine · 2010 · 382 citations

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger et al. · Leukemia · 2008 · 352 citations

Chronic Phase, Hematological Malignancy, Immunology +8

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

Cécile Pautas, Fatiha Merabet, Xavier Thomas et al. · Journal of Clinical Oncology · 2010 · 216 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Pharmacotherapy +16

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

Franck E. Nicolini, Sélim Corm, Q.H. Le et al. · Leukemia · 2006 · 203 citations

Hematological Malignancy, Medicine, Hematology +9

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

Jörge E. Cortes, D-W Kim, Emmanuel Raffoux et al. · Leukemia · 2008 · 198 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Oncology +6